So far, just 4 companies have a shot at winning the neuromodulation race

Neuromodulation is one of those medical device industry segments that's been around for a while. Generally, it involves implants through which electrical stimulation of the spinal cord, the brain or a peripheral nerve helps alleviate pain.

Neuromodulation is also one of those medical device industry segments that are poised for some major growth in the coming years, based on projections compiled by the research outfit EvaluateMedTech. Part of that comes as Medtronic ($MDT) and other companies explore a much wider use for the treatment, seeking to determine, for example, whether it can enable long-term relief (through deep brain stimulation) of Parkinson's-related symptoms. Neuromodulation also shows promise and gives hope as a potential treatment for depression and other psychiatric disorders. And the list goes on.

While a number of companies are pursuing neuromodulation technology development, there are four main global competitors. Medtronic is the industry leader in neuromodulation by a wide margin and will likely grow its lead even further through 2018, based on EvaluateMedTech data. But at least two other rivals are nipping furiously at Medtronic's heels, with a third generating healthy growth by focusing entirely on the neuromodulation space.

This report shows you where the four major neuromodulation players stand, and where they are projected to be by 2018. Beyond the EvaluateMedTech projections, we offer a snapshot of each of the major players, including the scope of their neuromodulation involvement, their recent milestones and which treatment indications they're betting on as they develop their neuromodulation technology.

Enjoy, thanks for reading and please, as always, let us know your thoughts.

Mark Hollmer (email | Twitter
Senior Editor, FierceMedicalDevices


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.